↓ Skip to main content

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in…

Overview of attention for article published in CNS Drugs, October 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#15 of 1,404)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
16 news outlets
policy
1 policy source
twitter
45 X users
patent
4 patents
facebook
4 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
308 Dimensions

Readers on

mendeley
447 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Published in
CNS Drugs, October 2018
DOI 10.1007/s40263-018-0578-5
Pubmed ID
Authors

Lesley Taylor, Barry Gidal, Graham Blakey, Bola Tayo, Gilmour Morrison

X Demographics

X Demographics

The data shown below were collected from the profiles of 45 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 447 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 447 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 65 15%
Student > Master 51 11%
Student > Bachelor 45 10%
Student > Ph. D. Student 45 10%
Other 41 9%
Other 50 11%
Unknown 150 34%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 72 16%
Medicine and Dentistry 60 13%
Biochemistry, Genetics and Molecular Biology 34 8%
Neuroscience 26 6%
Agricultural and Biological Sciences 17 4%
Other 70 16%
Unknown 168 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 164. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2023.
All research outputs
#257,040
of 25,978,998 outputs
Outputs from CNS Drugs
#15
of 1,404 outputs
Outputs of similar age
#5,197
of 365,841 outputs
Outputs of similar age from CNS Drugs
#1
of 21 outputs
Altmetric has tracked 25,978,998 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,404 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,841 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.